(Total Views: 436)
Posted On: 10/04/2024 11:36:59 AM
Post# of 148870
Jay's choice
"Trifluridine/tipiracil (TAS-102) plus bevacizumab is a third-line treatment for metastatic colorectal cancer (mCRC)".
The first and second lines are described as follows:
"Chemotherapy: The cornerstone of mCRC treatment, chemotherapy is used in combination with other agents. Some examples of chemotherapy drugs include fluorouracil (FU), oxaliplatin, and irinotecan.
Antiangiogenic agents: These agents are used in combination with chemotherapy.
Molecularly targeted agents: These agents are used in combination with chemotherapy.
Immune checkpoint inhibitors: These agents are used in the treatment of mCRC.
Anti-EGFR agents: These agents, such as cetuximab or panitumumab, are used in combination with chemotherapy for patients with wild-type RAS and BRAF."
As minimum, LL actions include inhibition of antiangiogenesis and immune checkpoints. Do we know why Dr. Lalezari has chosen to do the third line?
"Trifluridine/tipiracil (TAS-102) plus bevacizumab is a third-line treatment for metastatic colorectal cancer (mCRC)".
The first and second lines are described as follows:
"Chemotherapy: The cornerstone of mCRC treatment, chemotherapy is used in combination with other agents. Some examples of chemotherapy drugs include fluorouracil (FU), oxaliplatin, and irinotecan.
Antiangiogenic agents: These agents are used in combination with chemotherapy.
Molecularly targeted agents: These agents are used in combination with chemotherapy.
Immune checkpoint inhibitors: These agents are used in the treatment of mCRC.
Anti-EGFR agents: These agents, such as cetuximab or panitumumab, are used in combination with chemotherapy for patients with wild-type RAS and BRAF."
As minimum, LL actions include inhibition of antiangiogenesis and immune checkpoints. Do we know why Dr. Lalezari has chosen to do the third line?
(0)
(0)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼
